Down regulation and mutations in ROBO2 have been reported in prostate, gastric and colorectal cancers [33, 34]; while LAMA2 down regulation has been reported in drug-resistant ovarian cancer cell lines [35]. This evidence concerns the gene ROBO2 and ovarian carcinoma.